非S2P型SARS-CoV-2 mRNA疫苗LVRNA009在中国成年人中的I期研究
该单中心、双盲、安慰剂对照、剂量递增I期试验纳入72名18-59岁未接种疫苗的健康成年人,按3:1随机接受25、50或100 μg LVRNA009或安慰剂,两剂间隔28天。结果显示未报告高于2级的不良事件,发热和注射部位疼痛为最常见不良反应,三个剂量均可快速诱导体液和细胞免疫应答。
要点
- LVRNA009三个剂量组均未报告高于2级的不良事件。
- 首剂后14天诱生抗S蛋白IgG和中和抗体,第二剂后7天显著升高。
- 特异性T细胞应答在第二剂后7天达峰并持续至28天。
核心结论
- LVRNA009在中国成年人中三个剂量水平均显示出良好的安全性和耐受性,并能快速诱导体液和细胞免疫应答。
研究设计与样本
- 单中心、双盲、安慰剂对照、剂量递增I期试验,72名18-59岁健康未接种成年人按3:1随机接受25、50或100 μg LVRNA009或安慰剂,两剂间隔28天。
主要发现
- 研究期间未报告高于2级的不良事件。
- 接种后14天内30名参与者(42%)报告征集性不良反应。
- 发热(n=11,15%)为最常见的全身性不良反应,注射部位疼痛(n=17,24%)为最常见的征集性局部不良反应。
- 抗S蛋白IgG和中和抗体在首剂后14天被诱导,第二剂后7天显著升高,第二剂后28天维持高水平。
- 特异性T细胞应答在第二剂后7天达峰,并持续至第二剂后28天。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 caused by SARS-CoV-2 is a great threat to public health. We present the safety and immunogenicity data from a phase I trial in China of an mRNA vaccine (LVRNA009). METHODS: In the single-centre, double-blind, placebo-controlled and dose-escalation study, 72 healthy unvaccinated adults aged 18-59 years were randomized (3:1) to receive LVRNA009 with one of three vaccine dosage (25, 50 and 100 μg) or placebo, to evaluate for the safety, tolerability and immunogenicity of LVRNA009. RESULTS: All these participants received two injections 28 days apart. No adverse events higher than grade 2 were reported during the study. A total of 30 participants (42 %) reported solicited adverse reactions during the first 14 days after vaccinations. Of the events reported, fever (n = 11, 15 %) was the most common systemic adverse reaction, and pain at the injection site (n = 17, 24 %) was the most frequent solicited local adverse reaction. Anti-S-protein IgG and neutralising antibodies were observed to have been induced 14 days after the first dose, significantly increased 7 days after the second dose, and remained at a high level 28 days after the second dose. Specific T-cell responses peaked 7 days and persisted 28 days after second vaccination. CONCLUSION: LVRNA009 has demonstrated promising results in safety and tolerability at all three dose levels among Chinese adults. LVRNA009 at three dose levels could rapidly induce strong humoral and cellular immune responses, including binding and neutralising antibody production and IFN- γ secretion, which showed good immunogenicity. CLINICAL TRIAL REGISTRATION NUMBER: Clinicaltrials.gov NCT05364047; Chictr.org.cn ChiCTR2100049349.
引用
- Chen GL, Yu XY, Luo LP, et al. Phase I study of a non-S2P SARS-CoV-2 mRNA vaccine LVRNA009 in Chinese adults. Vaccine. 2023. PMID: 37925316. doi:10.1016/j.vaccine.2023.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。